Randomized Evaluation of Istaroxime for Stabilization in Acute Heart Failure-Cardiogenic Shock

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 600 participants.

Also called NCT07583446

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 600 participants (planned count) (from the registry)
Sponsor
Seismic Pharmaceuticals Operations LLC (from the registry)
Registry
  • NCT NCT07583446
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Armenia (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07583446. Randomized; quadruple masking; primary purpose treatment. Start 2026-09-09 (actual); primary completion 2028-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Randomized Evaluation of Istaroxime for Stabilization in Acute Heart Failure-Cardiogenic Shock
Acronym
RESCUE HF-CS
Condition
Cardiogenic Shock
Intervention (Drug)
istaroxime
Intervention (Drug)
placebo
Lead sponsor
Seismic Pharmaceuticals Operations LLC (class: industry)

Record details

Record id
cardio:ct-nct07583446
Content hash
43b2a51f3a97f22ff0e9e05e043ddfa73f8029430bbdc3dbc15c463261b242d0